This is the supplement-and-pharmacology layer of the 2026 Longevity Stack. It is intentionally sparse. The article ranks Tier 1 (cardio, resistance training, protein, sleep, cardiometabolic management) as the levers with the largest mortality effect. None of those are pills. The pharmacology layer below is what you add after Tier 1 is solid, and even then the additions are evidence-thin compared to the basics.
What is on the daily table
Only two supplements clear the bar: omega-3 (when the Omega-3 Index is below target) and vitamin D3 + K2 (when 25-OH vitamin D is measurably low). Both are gap-correction interventions, not blanket recommendations. The first move is dietary: fatty fish two to three times per week, ambient sun exposure ten or more minutes per morning. Test, then supplement to correct a measured deficit.
What is not on the table
Rapamycin is the most-discussed Tier 3 longevity intervention. It is weekly, off-label, requires a clinician, and the human healthspan trial base is one strong RCT in elderly immune function (Mannick 2018) plus observational signals. We list it in the disclaimers and the rapamycin compound entry rather than the daily stack table because a weekly Rx is a treatment decision, not a daily-stack decision.
GLP-1s (semaglutide, tirzepatide) have a longevity case only via cardiometabolic risk reduction in the right population. For healthy-BMI adults, the longevity rationale does not yet exist.
NAD+ precursors (NMN, NR), senolytics (dasatinib + quercetin, fisetin), and most peptides are Tier 3 in the source article: mechanistically interesting, RCT-thin or RCT-negative in humans. Not surfaced in the daily stack until a positive RCT lands.
How to sequence
Build the Tier 1 habit grid for the first 12 weeks. Add Tier 2 (sauna, social discipline) at week 13. Consider Tier 3 only after Tier 1 is stable. The stack table above is the conservative supplement layer; the Counter-view section of the source article walks through where Attia, Kaeberlein, and Longo each diverge from this baseline.